Skip to main content
×
Home
    • Aa
    • Aa
  • Primary Health Care Research & Development, Volume 11, Issue 1
  • January 2010, pp. 29-40

Monitoring and treatment for cardiovascular risk

  • Israel Rabinowitz (a1), Ohad Hochman (a1), Rachel Luzzati (a1), Yelena Haifitz (a1), Yuri Shclar (a1), Natalia Kaykov (a1), Alexander Khemlin (a1), Michael Kaffman (a1) and Ada Tamir (a1)
  • DOI: http://dx.doi.org/10.1017/S1463423609990338
  • Published online: 10 December 2009
Abstract
Background

In many countries there is a gap between the clinical evidence for cardiovascular disease (CVD) prevention and implementation in clinical practice. Inadequate control of cardiovascular risk factors and underutilization of aspirin, statins, angiotensin converting enzyme inhibitors and β-blockers are well-established examples. The optimal approach to implementation of CVD prevention in clinical practice is still under debate. The screening and monitoring (SaM) approach is based on cyclic monitoring and individual treatment of patients with cardiovascular risk factors in the primary care setting. After achieving improvements in risk factor levels and in the use of preventive medications in a pilot study, it was decided to test the efficacy of this approach in a larger population at risk.

Methods

Five primary care clinics adopted the SaM approach. A total of 1622 patients with established CVD, diabetes mellitus or hypertension were assessed by their family physicians for cardiovascular risk factors and use of medications for cardiovascular risk reduction. Interventions were made according to accepted clinical guidelines. Cardiovascular risk factor levels and the use of medications for CVD prevention were retrospectively analyzed.

Results

The results demonstrated significant reductions in blood pressure, hemoglobin A1c and low-density lipoprotein-cholesterol levels, as well as significant increases in the use of medications for CVD prevention.

Conclusion

A systematic approach to CVD reduction, with an emphasis on multiple risk factor assessment and use of preventive medications in patients at cardiovascular risk, yielded significant improvements in measures of the quality of preventive care.

Copyright
Corresponding author
Correspondence to: Israel Rabinowitz, Har Halutz, 20121 Israel. Email: Raly@netvision.net.il
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

ALLHAT Trial.2002: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of the American Medical Association 288, 29812997.

Antiplatelet Trialists’ Collaboration.1988: Secondary prevention of vascular disease by prolonged antiplatelet treatment. British Medical Journal 296, 320331.

Antiplatelet Trialists’ Collaboration.1994: Collaborative overview of randomized trials of antiplatelet therapy – I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 308, 81106.

D.M. Becker , L.R. Yanek , W.R. Johnson Jr. 2005: Impact of a community-based multiple risk factor intervention on cardiovascular risk in black families with a history of premature coronary disease. Circulation 111, 12981304.

J. Binns , D. Lanier , W.D. Pace , for the Primary Care Network Survey.2007: Describing Primary Care Encounters: the Primary Care Network Survey and the National Ambulatory Medical Care Survey. Annals of Family Medicine 5, 3947.

A.J.B. Brady , M.A. Oliver J.B. Pittard 2001: Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care. British Medical Journal 322, 1463.

M.D. Cabana , C.S. Rand , N.R. Powe 1999: Why don’t physicians follow clinical practice guidelines? A framework for improvement. Journal of the American Medical Association 282, 14581465.

M. Campbell , D. Reeves , E. Kontopantelis , B. Sibbald M. Roland 2009: Effect of Pay-for Performance on Quality of Primary Care in England. The New England Journal of Medicine 361, 368378.

T. Doran , C. Fullwood , H. Gravelle , D. Reeves , E. Kontopantelis , U. Hiroeh 2006: Pay-for-performance programs in family practices in the United Kingdom. The New England Journal of Medicine 355, 375384.

K. Eichler , M. Zoller , P. Tschudi J. Steurer 2007: Barriers to apply cardiovascular prediction rules in primary care: a postal survey. BMC Family Practice 8, 17.

L.R. Erhardt 1999: The essence of effective treatment and compliance is simplicity. American Journal of Hypertension 12, 105s110s.

EUROASPIRE II Study Group.2001: Lifestyle and risk factor management and use of drug therapy in coronary patients from 15 countries; principle results from the EUROASPIRE II Euro Heart Survey Program. European Heart Journal 22, 554572.

H.H. Feringa , V.H. van Wanin , J.J. Bax 2006: Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. Journal of the American College of Cardiology 47, 11821187.

P. Gaede , H. Lund-Andersen , H.H. Parving O. Pedersen 2008: Effect of a multifactorial intervention on mortaliy in type 2 diabetes. The New England Journal of Medicine 358, 580591.

Heart Protection Study Collaborative Group.2002: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 722.

P.R. Hebert , J.M. Gaziano , K.S. Chan C.H. Hennekens 1997: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. Journal of the American Medical Association 278, 313321.

J. Hippisley-Cox C. Coupland 2005: Effect of combinations of drugs on all cause mortality: nested case-control analysis in patients with ischemic heart disease. British Medical Journal 330, 10591063.

D.J. Hyman V.N. Pavlik 2000: Self reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices and the role of guidelines and evidence-based medicine. Archives of Internal Medicine 160, 22812286.

A.J. Kerr , J. Broad , S. Wells , T. Riddell R.T. Jackson 2009: Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart 95, 125129.

J.C. LaRosa , S.M. Grundy , D.D. Waters 2005: Intensive lipid lowering with Atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 352, 14251435.

Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group.1998: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The New England Journal of Medicine 339, 13491357.

F.M. Sacks , M.A. Pfeffer , L.A. Moye 1996: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England Journal of Medicine 335, 10011009.

T.D. Sequist , T.K. Gandhi , A.S. Karson 2005: A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary artery disease. Journal of the American Medical Informatics Association 12, 431437.

SHEP Cooperative Research Group.1991: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). Journal of the American Medical Association 265, 32553264.

S.L. Sheridan E. Crespo 2008: Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harm? A systematic review of the literature. BMC Health Services Research 8, 6073.

J.A. Staessen , R. Fagard , L. Thijs , for the Systolic Hypertension in Europe Trial Investigators.1997: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350, 757764.

R.S. Stafford D.C. Radley 2003: The underutilization of cardiac medications of proven benefit – 1990 to 2002. Journal of the American College of Cardiology 41, 5661.

I.M. Stratton , A.I. Adler , H.A. Neil 2000: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321, 405412.

UK Prospective Diabetes Study Group.1998: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 317, 703713.

L. Whiteley , S. Padmanabhan , D. Hole C. Isles 2005: Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 28, 15881593.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Primary Health Care Research & Development
  • ISSN: 1463-4236
  • EISSN: 1477-1128
  • URL: /core/journals/primary-health-care-research-and-development
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: